Healthcare Business

Why Catalyst Bio Nearly Tripled

Catalyst Biosciences Inc. (NASDAQ: CBIO) saw its shares practically triple in Tuesday’s session after the company announced a critical regulatory approval. The company reported that the Korean Ministry of Food ...
Read Full Story »

Short Interest Pulls Back in Major Biotechs

The short interest data are out for the most recent settlement date, March 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Major Pharma Short Sellers Couldn’t Make Up Their Minds Before Failed Trump Health Care Vote

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Analyst Calls for Exponential Upside for Idera Pharmaceuticals

Idera Pharmaceuticals Inc. (NASDAQ: IDRA) is focused on cancer and rare diseases, and it could be a what traders refer to as a three-bagger or four-bagger, if two analysts who ...
Read Full Story »

How Health Care Stocks Responded to the Shelved Health Care Bill

Despite touting himself as an incredible dealmaker and negotiater, Trump faced the biggest defeat of his presidency thus far when legislation to repeal the Affordable Care Act was pulled from ...
Read Full Story »

2 Health Care Stocks Crushed on Thursday

The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the campaign trail. But 2017 could be different, with a new ...
Read Full Story »

How a Key European Decision Is Making All the Difference at HTG

HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) saw its shares make a massive move to the upside after the company announced that it has obtained CE Marking in the European Union ...
Read Full Story »

Regenxbio Sinks After Announcing Secondary Offering

Regenxbio Inc. (NASDAQ: RGNX) saw its shares drop handily after the firm announced the pricing of its secondary offering. The company plans to offer 3.7 million shares of common stock ...
Read Full Story »

Why Pulmatrix Investors Are Breathing a Sigh of Relief

Pulmatrix Inc. (NASDAQ: PULM) saw its shares take a massive jump on Tuesday after the company announced that it received a crucial patent approval in Europe. Essentially the EU patent ...
Read Full Story »

5 Biotech Stocks That Could Skyrocket From Upcoming Catalysts

Needless to say, the biotech world has had a very difficult 18 months. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have ...
Read Full Story »

Monday’s Top Biopharma Movers

A few biopharma stocks made massive runs on Monday morning. The broad markets are holding near their all-time highs, and part of the run up to this level is attributed ...
Read Full Story »

Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now

If any sector is offering value in what really appears to be a very overbought stock market, it is pharmaceutical, including biotechnology. Absolutely battered during the election cycle when rhetoric over ...
Read Full Story »

Wednesday’s Biggest Biopharma Movers

The broad markets inched forward on Wednesday after hitting new highs in what has been known as the Trump rally. Although the SPDR S&P Biotech ETF (NYSEMKT: XBI) was up ...
Read Full Story »

Is Valeant Finished Now That Ackman Is Out of the Picture?

Valeant Pharmaceuticals International Inc. (NYSE: VRX) saw its shares hit a multiyear low on Tuesday after it was announced that Bill Ackman would be selling off his stake in the ...
Read Full Story »

What a Combined Gilead and Incyte Would Look Like

Gilead Sciences Inc. (NASDAQ: GILD) has long been in need of a catalyst to move its business, and a lot of investors and analysts alike have considered this company dead ...
Read Full Story »